Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimer’s disease progression
Open accessAbstract
Background: Alzheimer’s disease (AD) is the most common type of dementia, with progressive onset of clinical symptoms. The main pathological hallmarks are brain deposits of extracellular amyloid beta plaques and intracellular neurofibrillary tangles (NFT). Cerebrospinal fluid reflects pathological changes in the brain; amyloid beta 1-42 is a marker of amyloid plaques, while total and phosphorylated tau are markers of NFT formation. Additional biomarkers associated with disease pathogenesis are needed, for better prognosis, more specific diagnosis, prediction of disease severity and progression and for improved patient classification in clinical trials. The aim of the present study was to evaluate brain-specific proteins as potential biomarkers of progression of AD. Methods: Overall, 30 candidate proteins were quantified in cerebrospinal fluid (CSF) samples from patients with mild cognitive impairment (MCI) and mild, moderate and severe AD dementia (n=101) using mass spectrometry-based selected reaction monitoring assays. ELISA was used for neuronal pentraxin receptor-1 (NPTXR) confirmation. Results: The best discrimination between MCI and more advanced AD stages (moderate and severe dementia) was observed for protein NPTXR (area under the curve, AUC=0.799). A statistically different abundance of this protein was observed between the two groups, with severe AD patients having progressively lower levels (p<0.05). ELISA confirmed lower levels in AD, in a separate cohort that included controls, MCI and AD patients. Conclusions: We conclude that NPTXR protein in CSF is a novel potential biomarker of AD progression and could have important utility in assessing treatment success in clinical trials.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Recent studies in cerebrospinal fluid revealed altered NPTXs levels in several neurodegenerative disorders.
“Recent studies in cerebrospinal fluid (CSF) revealed altered NPTXs levels in several neurodegenerative disorders.”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Begcevic et al. 2018
CSF NPTXR can discriminate between advanced AD stages and MCI (Area under the curve = 0.799).
“Accordingly, CSF NPTXR can discriminate between advanced AD stages and MCI (Area under the curve = 0.799) (Begcevic et al. 2018; Lim et al. 2019).”
From Neuronal pentraxins as biomarkers of synaptic activity: from physiological functions to pathological changes in neurodegeneration (2022) · cites this paper as Begcevic et al. 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · see citing works
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286 · see citing works
Mild Cognitive Impairment: Clinical Characterization and Outcome
Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., & Kokmen, E. (1999) · Archives of Neurology · doi:10.1001/archneur.56.3.303 · Cited by 8,980 · see citing works
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459 · see citing works
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134 · see citing works
Ballard, C., Gauthier, S., Corbett, A., Brayne, C., Aarsland, D., & Jones, E. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61349-9 · Cited by 2,336 · see citing works
Jack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042 · see citing works
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863 · see citing works
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · see citing works
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681 · see citing works
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525 · see citing works
Wang, E., Yao, H.-B., Chen, Y., Wang, G., Gao, W., Sun, Y., Guo, J., Hu, J., Jiang, C., & Hu, J. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350082 · Cited by 1,176 · see citing works
Dodds, D. C., Omeis, I. A., Cushman, S. J., Helms, J. A., & Perin, M. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.21488 · Cited by 170 · see citing works
Drabovich, A. P., Dimitromanolakis, A., Saraon, P., Soosaipillai, A. R., Batruch, I., Mullen, B. M., Jarvi, K. A., & Diamandis, E. P. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006260 · Cited by 169 · see citing works
Self-citationAccommodating Covariates in Receiver Operating Characteristic Analysis
Janes, H., Longton, G., & PEPE, M. S. (2009) · The Stata Journal Promoting communications on statistics and Stata · doi:10.1177/1536867x0900900102 · Cited by 163 · see citing works
Kroksveen, A. C., Opsahl, J. A., Aye, T. T., Ulvik, R. J., & Berven, F. S. (2010) · Journal of Proteomics · doi:10.1016/j.jprot.2010.11.010 · Cited by 154 · see citing works
Presynaptic neuronal pentraxin receptor organizes excitatory and inhibitory synapses
Lee, S.-J., Wei, M., Zhang, C., Maxeiner, S., Pak, C., Calado Botelho, S., Trotter, J., Sterky, F. H., & Südhof, T. C. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.2768-16.2016 · Cited by 146 · see citing works
Yin, G. N., Lee, H. W., Cho, J.-Y., & Suk, K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.01.058 · Cited by 143 · see citing works
Wildsmith, K. R., Schauer, S. P., Smith, A. M., Arnott, D. P., Zhu, Y., Haznedar, J., Kaur, S., Mathews, W. R., & Honigberg, L. A. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-22 · Cited by 140 · see citing works
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects
Toledo, J. B., Zetterberg, H., van Harten, A. C., Glodzik, L., Martinez-Lage, P., Bocchio-Chiavetto, L., Rami, L., Hansson, O., Sperling, R., Engelborghs, S., et al. (2015) · Brain · doi:10.1093/brain/awv199 · Cited by 136 · see citing works
<i>APOE</i> ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42
Prince, J. A., Zetterberg, H., Andreasen, N., Marcusson, J., & Blennow, K. (2004) · Neurology · doi:10.1212/01.wnl.0000128088.08695.05 · Cited by 128 · see citing works
Ringman, J. M. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.642 · Cited by 124 · see citing works
Longitudinal stability of CSF tau levels in Alzheimer patients
Sunderland, T., Wolozin, B. L., Galasko, D., Levy, J., Dukoff, R. A., Bahro, M., Lasser, R. A., Motter, R. N., Lehtimäki, T. J., & Seubert, P. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00143-2 · Cited by 108 · see citing works
Begcevic, I., Brinc, D., Drabovich, A. P., Batruch, I., & Diamandis, E. P. (2016) · Clinical Proteomics · doi:10.1186/s12014-016-9111-3 · Cited by 84 · see citing works
Self-citationBegcevic, I., Brinc, D., Brown, M., Martinez-Morillo, E., Goldhardt, O., Grimmer, T., Magdolen, V., Batruch, I., & Diamandis, E. P. (2018) · Journal of Proteomics · doi:10.1016/j.jprot.2018.04.027 · Cited by 81 · see citing works
Self-citationA comprehensive map and functional annotation of the normal human cerebrospinal fluid proteome
Zhang, Y., Guo, Z., Zou, L., Yang, Y., Zhang, L., Ji, N., Shao, C., Sun, W., & Wang, Y. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.01.017 · Cited by 78 · see citing works
Hendrickson, R. C., Lee, A. Y. H., Song, Q., Liaw, A. I., Wiener, M., Paweletz, C. P., Seeburger, J. L., Li, J., Meng, F., Deyanova, E. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135365 · Cited by 68 · see citing works
Martínez‐Morillo, E., Nielsen, H. M., Batruch, I., Drabovich, A. P., Begcevic, I., Lopez, M. F., Minthon, L., Bu, G., Mattsson, N., Portelius, E., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr401060x · Cited by 67 · see citing works
Self-citationKhan, T. K., & Alkon, D. L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150238 · Cited by 61 · see citing works
Martínez‐Morillo, E., Hernández, P. G., Begcevic, I., Kosanam, H., García, B. P., Menéndez, F. V. Á., & Diamandis, E. P. (2013) · Journal of Proteome Research · doi:10.1021/pr401111h · Cited by 35 · see citing works
Self-citationBegcevic, I., Brinc, D., Dukić, L., Šimundić, A.-M., Zavoreo, I., Kes, V. B., Martínez‐Morillo, E., Batruch, I., Drabovich, A. P., & Diamandis, E. P. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00768 · Cited by 28 · see citing works
Self-citationWilliams, J. H., Wilcock, G. K., Seeburger, J. L., Dallob, A. L., Laterza, O., Potter, W. Z., & Smith, A. D. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt64 · Cited by 26 · see citing works
Begcevic, I., Tsolaki, M., Brinc, D., Brown, M., Martínez‐Morillo, E., Lazarou, I., Kozori, M., Tagaraki, F., Nenopoulou, S., Γκιόκα, Μ., et al. (2025) · doi:10.5256/f1000research.15095.d208304 · Cited by 1 · see citing works
Self-citation
Flagged first, then by citations
1 of the 35 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- [23]Janes H Longton G Pepe M: Accommodating Covariates in ROC Analysis. Stata J. 2009; 9(1): 17– 39. 20046933 PMC2758790
Cited by
Sorted by citations
Fluid Biomarkers for Synaptic Dysfunction and Loss
Camporesi, E., Nilsson, J., Brinkmalm, A., Becker, B., Ashton, N. J., Blennow, K., & Zetterberg, H. (2020) · Biomarker Insights · doi:10.1177/1177271920950319 · Cited by 165 · see citing works
Epidemiology of Alzheimer’s disease and other dementias: rising global burden and forecasted trends
Javaid, S. F., Giebel, C. M., Khan, M. A., & Hashim, M. J. (2021) · F1000Research · doi:10.12688/f1000research.50786.1 · Cited by 161 · see citing works
Galasko, D., Xiao, M., Xu, D., Smirnov, D., Salmon, D. P., Dewit, N., Vanbrabant, J., Jacobs, D., Vanderstichele, H., Vanmechelen, E., et al. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.11.002 · Cited by 133 · see citing works
Gómez de San José, N., Massa, F., Halbgebauer, S., Oeckl, P., Steinacker, P., & Otto, M. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-021-02411-2 · Cited by 112 · see citing works
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
van der Ende, E. L., Xiao, M., Xu, D., Poos, J. M., Panman, J. L., Jiskoot, L. C., Meeter, L. H., Dopper, E. G., Papma, J. M., Heller, C., et al. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2019-322493 · Cited by 94 · see citing works
Cerebrospinal fluid biomarker panel for synaptic dysfunction in Alzheimer's disease
Nilsson, J., Gobom, J., Sjödin, S., Brinkmalm, G., Ashton, N. J., Svensson, J., Johansson, P., Portelius, E., Zetterberg, H., Blennow, K., et al. (2021) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12179 · Cited by 82 · see citing works
Nilsson, J., Binette, A. P., Palmqvist, S., Brum, W. S., Janelidze, S., Ashton, N. J., Spotorno, N., Stomrud, E., Gobom, J., Zetterberg, H., et al. (2024) · Brain · doi:10.1093/brain/awae032 · Cited by 82 · see citing works
The Basic Characteristics of the Pentraxin Family and Their Functions in Tumor Progression
Wang, Z., Wang, X., Zou, H., Dai, Z., Feng, S., Zhang, M., Xiao, G., Liu, Z., & Cheng, Q. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01757 · Cited by 73 · see citing works
Kluever, V., Russo, B., Mandad, S., Kumar, N. H., Alevra, M., Ori, A., Rizzoli, S. O., Urlaub, H., Schneider, A., & Fornasiero, E. F. (2022) · Science Advances · doi:10.1126/sciadv.abn4437 · Cited by 69 · see citing works
A comprehensive systematic review of CSF proteins and peptides that define Alzheimer’s disease
Pedrero-Prieto, C. M., García‐Carpintero, S., Frontiñán-Rubio, J., Llanos-González, E., García, C. A., Alcain, F. J., Lindberg, I., Durán‐Prado, M., Peinado, J. R., & Rabanal‐Ruiz, Y. (2020) · Clinical Proteomics · doi:10.1186/s12014-020-09276-9 · Cited by 61 · see citing works
Nilsson, J., Cousins, K. A. Q., Gobom, J., Portelius, E., Chen‐Plotkin, A. S., Shaw, L. M. J., Grossman, M., Irwin, D. J., Trojanowski, J. Q., Zetterberg, H., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12809 · Cited by 61 · see citing works
From Recognition to Remedy: The Significance of Biomarkers in Neurodegenerative Disease Pathology
Toader, C., Dobrin, N., Brehar, F.-M., Popa, C., Covache-Busuioc, R.-A., Glavan, L.-A., Costin, H. P., Bratu, B.-G., Corlatescu, A.-D., Popa, A. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216119 · Cited by 61 · see citing works
Cilento, E. M., Jin, L., Stewart, T., Shi, M., Sheng, L., & Zhang, J. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14635 · Cited by 60 · see citing works
Nilsson, J., Constantinescu, J., Nellgård, B., Jakobsson, P., Brum, W. S., Gobom, J., Forsgren, L., Dalla, K., Constantinescu, R., Zetterberg, H., et al. (2022) · Movement Disorders · doi:10.1002/mds.29287 · Cited by 56 · see citing works
Multi‐cohort profiling reveals elevated CSF levels of brain‐enriched proteins in Alzheimer’s disease
Bergström, S., Remnestål, J., Yousef, J., Olofsson, J., Markaki, I., Carvalho, S., Corvol, J., Kultima, K., Kilander, L., Löwenmark, M., et al. (2021) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51402 · Cited by 48 · see citing works
Kovács, R. Á., Vadászi, H., Bulyáki, É., Török, G., Tóth, V., Mátyás, D., Kun, J., Hunyadi-Gulyás, É., Fedor, F. Z., Csincsi, Á., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599771 · Cited by 43 · see citing works
Sogorb-Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., van Swieten, J. C., Seelaar, H., et al. (2022) · Alzheimer's Research & Therapy · doi:10.1186/s13195-022-01042-3 · Cited by 39 · see citing works
Lim, B., Sando, S. B., Grøntvedt, G. R., Bråthen, G., & Diamandis, E. P. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.013 · Cited by 39 · see citing works
Self-citationBiomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 37 · see citing works
Dulewicz, M., Kulczyńska‐Przybik, A., & Mroczko, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21218335 · Cited by 34 · see citing works
Lim, B., Tsolaki, M., Soosaipillai, A., Brown, M., Zilakaki, M., Tagaraki, F., Fotiou, D., Koutsouraki, E., Grosi, E., Prassas, I., et al. (2019) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-0428 · Cited by 25 · see citing works
Self-citationDulewicz, M., Kulczyńska-Przybik, A., Słowik, A., Borawska, R., & Mroczko, B. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194575 · Cited by 22 · see citing works
Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds
Remnestål, J., Bergström, S., Olofsson, J., Sjöstedt, E., Uhlén, M., Blennow, K., Zetterberg, H., Zettergren, A., Kern, S., Skoog, I. G., et al. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00789-5 · Cited by 16 · see citing works
Schauer, S. P., Tóth, B. I., Lee, J., Honigberg, L. A., Ramakrishnan, V., Jiang, J. Z., Kollmorgen, G., Bayfield, A., Wild, N., Hoffman, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14346 · Cited by 17 · see citing works
Batruch, I., Lim, B., Soosaipillai, A. R., Brinc, D., Fiala, C., & Diamandis, E. P. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00087 · Cited by 11 · see citing works
Self-citationSaunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12 · see citing works
Warpechowski, M., Warpechowski, J. J., Kulczyńska‐Przybik, A., & Mroczko, B. (2022) · Medical Science Monitor · doi:10.12659/msm.938826 · Cited by 11 · see citing works
Zhu, S., Bäckström, D., Forsgren, L., & Trupp, M. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-213031 · Cited by 10 · see citing works
Lim, B., Fowler, C., Li, Q.-X., Rowe, C., Dhiman, K., Gupta, V. B., Masters, C. L., Doecke, J. D., Martins, R. N., Collins, S., et al. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.135078 · Cited by 10 · see citing works
Self-citationBiomarkers and Their Implications in Alzheimer’s Disease: A Literature Review
Marcucci, V., & Kleiman, J. (2021) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2021.00016 · Cited by 8 · see citing works
Nilsson, J., Mecca, A. P., Ashton, N. J., Salardini, E., O’Dell, R. S., Carson, R. E., Benedet, A. L., Blennow, K., Zetterberg, H., van Dyck, C. H., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70403 · Cited by 6 · see citing works
Afxenti, S., Zachariou, M., Athieniti, E., Lambrianides, A., Pantzaris, M., & Spyrou, G. M. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06937-x · Cited by 6 · see citing works
Stratifying risk of Alzheimer’s disease in healthy middle-aged individuals with machine learning
Tandon, R., Zhao, L., Watson, C. M., Sarkar, N., Elmor, M. B., Heilman, C. J., Sanders, K., Hales, C. M., Yang, H., Loring, D. W., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf121 · Cited by 6 · see citing works
Guo, Z., Hong, X., Wang, X., Chen, W., & Guo, Z. (2024) · Aging Clinical and Experimental Research · doi:10.1007/s40520-023-02670-x · Cited by 5 · see citing works
Sogorb‐Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Russell, L. L., Peakman, G., Convery, R. S., Swieten, J. C. V., Seelaar, H., Borroni, B., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1188941/v1 · Cited by 5 · see citing works
Mapping the human brain proteome: opportunities, challenges, and clinical potential
Cartas‐Cejudo, P., Cortés, A., Lachén‐Montes, M., Anaya‐Cubero, E., Peral, E., Ausín, K., Díaz, R., Fernández‐Irigoyen, J., & Santamaría, E. (2024) · Expert Review of Proteomics · doi:10.1080/14789450.2024.2313073 · Cited by 4 · see citing works
Lah, J. J., Tandon, R., Zhao, L., Watson, C. M., Elmor, M. B., Heilman, C. J., Sanders, K., Hales, C. M., Yang, H., Loring, D. W., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-2577025/v1 · Cited by 4 · see citing works
A compilation of reported alterations in the cerebrospinal fluid proteome in Alzheimer's disease
de Geus, M. B., Nairn, A. C., Arnold, S. E., & Carlyle, B. C. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf202 · Cited by 3 · see citing works
Dai, L., Kirsebom, B., Wang, C., Zhang, M., Wang, Q., Ni, M., González‐Ortiz, F., Blennow, K., Shi, J., Fladby, T., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-70472-6 · Cited by 3 · see citing works
The Role of Pentraxin 3 in Gastrointestinal Cancers
Zajkowska, M., & Mroczko, B. (2023) · Cancers · doi:10.3390/cancers15245832 · Cited by 3 · see citing works
Proteomic Insights into Heroin Use: Links to Neurodegeneration
Sürmen, M. G., Pençe, S., Sürmen, S., Büyük, Y., Kuraş, S., Elibol, B., & Pençe, H. H. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-05757-4 · Cited by 1 · see citing works
Stezin, A., Sathe, G. J., Gajbhiye, A., Bhardwaj, S., Ghose, V., Bellad, A., Malo, P. K., Holla, V. V., Hegde, S., Bharath, R. D., et al. (2024) · Movement Disorders · doi:10.1002/mds.29834 · Cited by 1 · see citing works
Clinical Validation of Neuronal Pentraxin Receptor as a Candidate Biomarker for Alzheimer’s Disease
Lim, B. (2020) · TSpace (University of Toronto)
Self-citationSogorb‐Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Russell, L. L., Peakman, G., Convery, R. S., Swieten, J. C. V., Seelaar, H., Borroni, B., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1188941/v2
Diagnostic and progression biomarkers in cerebrospinal fluid of Alzheimer’s disease patients
Chatanaka, M. K., Prassas, I., & Diamandis, E. P. (2024) · BMC Medicine · doi:10.1186/s12916-024-03270-w
Self-citationFluid and Imaging Markers of Synaptic Injury
Tarawneh, R. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-80849-4_4
Sogorb‐Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., Swieten, J. C. V., Seelaar, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20762867
Sogorb‐Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., Swieten, J. C. V., Seelaar, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20762873
Sogorb‐Esteve, A., Nilsson, J., Swift, I. J., Heller, C., Bocchetta, M., Russell, L. L., Peakman, G., Convery, R. S., Swieten, J. C. V., Seelaar, H., et al. (2022) · Figshare · doi:10.6084/m9.figshare.20762870
Backbone resonance assignment of the pentraxin domain of the neuronal pentraxin receptor (NPTXR)
Pozhidaeva, A., Li, Y., Pustovalova, Y. E., Hoch, J. C., Martinelli, D. C., Simon, B., & Hao, B. (2026) · Biomolecular NMR Assignments · doi:10.1007/s12104-025-10259-w
- Authors
- Begcevic, I., Tsolaki, M., Brinc, D., Brown, M., Martinez-Morillo, E., Lazarou, I., Kozori, M., Tagaraki, F., Nenopoulou, S., Gkioka, M., Lazarou, E., Lim, B., Batruch, I., & Diamandis, E. P.
- Affiliations
- Mount Sinai Hospital (CA)
- Aristotle University of Thessaloniki (GR)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Diamandis, Eleftherios P.
- Venue
- F1000Research
- Publisher
- F1000 Research Ltd
- Published
- 2018-07-05
- Volume
- 7
- Pages
- 1012
- ISSN
- 2046-1402 (ISSN-L)
- PMC
- PMC6081984
- OpenAlex
- W2848858403
- Cited by
- 51
- References
- 35
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 12 · 2021: 8 · 2020: 10 · 2019: 2 · 2018: 2
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- F1000Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Mount Sinai Hospital
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, cerebrospinal fluid biomarkers, disease progression, mild cognitive impairment, amyloid plaques, neurofibrillary tangles, tau phosphorylation, brain-specific proteins, dementia severity
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Receptors, Cell Surface, Retrospective Studies, Biomarkers, Amyloid beta-Peptides, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
